Key Takeaways
- Price-led miss, not volume: Non-ibuprofen revenue will fall short of the ₹500 crore target, landing around ₹450 crore, solely because Paracetamol prices collapsed 35–40% YoY; quantities are still growing.
- Margins squeezed by realizations, not costs: Gross margin contracted QoQ as finished-goods prices fell faster than input costs, which management says have now bottomed out.
- Paracetamol pain may be peaking: Prices have returned to pre-COVID levels and management believes they are stabilized and bottomed, with a recovery possible from Q4 FY24.
- Regulatory progress, but no near-term revenue: The Losartan CEP opens Europe, yet there is no dedicated plant and commercial orders are two to three quarters away.
- What to watch next quarter: Whether Paracetamol prices actually recover as guided, the pace of export order conversion from customer validations, and how much of the Red Sea freight cost can be passed through.
The Paracetamol Price Shock
- Magnitude of the decline: Paracetamol prices dropped 35% to 40% from last year, returning to pre-COVID levels. This single product is the primary reason non-ibuprofen revenue will miss the ₹500 crore full-year target, with management now guiding to roughly ₹450 crore.
- Volume vs value: Quantity is still growing, so the entire API segment de-growth, both YoY and QoQ, is a price-realization story, not a demand-destruction one.
- Competitive shakeout expected: Management argues that at these prices, viability for many players may not remain, and IOL's backward integration for Paracetamol gives it an edge that should help once the shakeout runs its course.
- The bottoming call: Input prices have also declined in ratio with finished-goods prices, and management sees no further reduction in input costs, calling both input and output prices bottomed.
Mahajan: "The Paracetamol prices primarily have come near to pre-COVID level, demand is still there, but prices are drastically down from last year's price by 35% to 40%. Although we think that the prices are now stabilized and bottomed out."
Margin Walk
- Gross margin driver: The QoQ decline in gross margin is attributed mainly to lower price realization of non-ibuprofen APIs, especially Paracetamol. Input prices declined in the same ratio, which limited the damage but did not prevent contraction.
- Specialty chemicals still soft: The specialty chemical sector has not recovered as anticipated, with signs of demand weakness and volatility. Acetic Anhydride, commercialized two quarters ago, faces agrochemical market pressure from China and is expected to remain under pressure for a couple more quarters before contributing meaningfully.
- Red Sea cost headwind: Freight and insurance costs rose due to the Red Sea crisis, with delivery times extended by three to four weeks for exports. On already contracted orders, the company is absorbing the cost; for upcoming contracts, it is negotiating to pass costs to customers. These elevated costs are expected to persist in Q4 FY24.
- Q4 margin outlook: Some improvement in EBITDA margins is expected in Q4, though management declined to quantify it.
Mahajan: "For already contracted orders the amount is being borne by the company but for upcoming contracts we are negotiating with our customers for passing on these costs to them."
Non-Ibuprofen: The Export Pivot
- The revenue bridge to growth: Management is targeting roughly 25% revenue growth from the non-ibuprofen segment over the next two to three years, with export sales to regulated markets as the primary driver.
- Customer validation underway: Seeding has started with various customers, and management expects commercial orders to begin flowing within two to three quarters, with export sales becoming visible in Q1 or Q2 FY25.
- Margin uplift from regulated markets: Net sales realization is expected to increase when exporting to European and other regulated markets. The margin difference varies by product: some see only a marginal improvement, others command 20–25% higher margins. On average, gross margins should improve once the export business in the non-ibuprofen segment stabilizes.
- Losartan CEP: The CEP certificate for the European market was received in the week of the call. There is no dedicated plant yet; production runs on a campaign basis in a multi-project facility. A dedicated plant will be considered only after demand and customer validation materialize over the coming two to three quarters.
Singh: "Initially we were targeting about ₹500 crore revenue from non-ibuprofen products this year, but considering the current market situation it looks tough. We will not be able to clock ₹500 crore revenue from non-ibuprofen but surely we will be able to do something around ₹450 crore."
Ibuprofen & Capacity Utilization
- Utilization dipped seasonally: Q3 capacity utilization was lower because the last month of the calendar year sees overseas markets slow on the buying side due to holidays. Q4 and Q1 of the next financial year usually see better ibuprofen quantity sales.
- Utilization outlook: 85% utilization is expected to be maintained over the next two quarters, with the ability to scale to 95% if a demand surge materializes.
- Overall top-line ambition: The company is targeting 10% to 12% annual top-line growth as a whole, with the non-ibuprofen segment expected to be the faster-growing piece.
Pipeline & Capacity Plans
- Eight products in the pipeline: These will not all launch in one or two years; the approach is to first manufacture in multiproduct facilities, then set up dedicated plants only when good demand is visible. No revenue guidance was offered for these products.
- Paracetamol capacity expansion on hold: No decision has been taken on capacity enhancement for Paracetamol, and management declined to provide any update, citing the need to assess the market situation first.
- IOL UK subsidiary wound down: The UK subsidiary was opened and then closed after management concluded the UK is not the right destination, particularly since it is no longer in the EU. Alternative plans will be communicated at an appropriate time.
- FY25 CAPEX: Planned at ₹150 to ₹200 crore, funded primarily from internal accruals.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Non-ibuprofen revenue | ~₹450 crore (down from ₹500 crore guided earlier) | FY24 full year |
| Paracetamol price recovery | Prices bottomed; product price likely to improve | From Q4 FY24 |
| API segment price recovery | Prices bottomed; recovery expected | Next two quarters |
| Export sales visibility | Commercial orders from customer validations | Q1 or Q2 FY25 |
| Non-ibuprofen revenue growth | ~25% growth | Next two to three years |
| Ibuprofen capacity utilization | 85% maintained; scalable to 95% on demand surge | Next two quarters |
| Overall top-line growth | 10–12% annual | Ongoing target |
| FY25 CAPEX | ₹150–200 crore, funded from internal accruals | FY25 |
| EBITDA margins | Some improvement expected | Q4 FY24 |
| EBIT margin (API segment) | A little higher from current level, aided by regulatory approvals and export mix | FY25 |
| Acetic Anhydride contribution | Pressure expected before meaningful topline contribution | Couple more quarters |
Key Metrics
| Metric | Q3 FY24 |
|---|---|
| Total income | ₹529 cr, flat YoY vs ₹530 cr, down 4.2% QoQ from ₹552 cr |
| EBITDA | ₹53 cr, up 6% YoY from ₹50 cr, down 25.4% QoQ from ₹71 cr |
| EBITDA margin | 10.0%, up 60 bps YoY from 9.4%, down from 12.9% QoQ |
| Net profit | ₹23 cr, down 4.2% YoY from ₹24 cr, down 39.5% QoQ from ₹38 cr |
| EBIT margin, pharmaceutical segment | 12.19% |
| EBIT margin, specialty chemicals segment | 0.43% |
| CAPEX | ₹80 cr, vs ₹75 cr in Q3 FY23 and ₹82 cr in Q2 FY24 |
| Annual CAPEX guidance | ₹150–200 cr, funded entirely from internal accruals |
| Non-ibuprofen API revenue | Sub-₹100 cr for the quarter |
| Non-ibuprofen share of topline | ~21% |
| Ibuprofen capacity utilization | 85%, lower due to year-end holiday slowdown in overseas markets |
| Ibuprofen net realization | ~US$10, stable |
| Paracetamol price realization | Down 35–40% vs Q4 FY23, now near pre-COVID levels |
| Non-ibuprofen FY24 revenue target | ~₹450 cr, revised down from initial ₹500 cr guidance |
| Ethyl Acetate price change | Up 0.5–1%, stabilized |